The era of biological medicines
Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide, millions of patients have already benefited from approved biological medicines, but what exactly are they, and how are they produced?

Open

Biological medicines ― the major social and economic challenges
The global spend on pharmaceuticals continues to increase. The use of biological medicines offers new treatment choices to patients, but at a high financial cost. What are the challenges faced by payers and physicians in preserving access to biological medicines within a financially constrained healthcare system?

Open

Biosimilar medicines — rising to the cost challenge
Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe.
Biosimilar medicines are providing more cost-effective biological treatments, but what are biosimilar medicines, and how do they meet this challenge?

Open

Biosimilar medicines — a commitment to scientific excellence
With biosimilar medicines, patients and healthcare providers benefit from high quality and efficacious therapeutic alternatives.
But how are biosimilar medicines developed, and how is their efficacy and safety ensured?

Open

The benefits of biosimilar medicines
Biosimilar medicines have demonstrated similarity with reference biologicals in terms of structure, function, safety and efficacy, but what are their benefits?

Open

Building on the experience and success of biosimilar medicines
Biosimilar medicines are increasingly becoming an integral part of modern healthcare systems, so what does the future hold?

Open

If you wish to use any part of this slide deck, please contact us at igba@igbamedicines.org. We would be happy to share this with you.

Share this
Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInPin on PinterestBuffer this pageEmail this to someone